NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Monday that Cigna has issued a positive coverage decision for the Afirma Gene Expression Classifier test.

The decision means that about 13 million Cigna customers will have access to Veracyte's thyroid cancer test as a covered benefit. Cigna's policy takes effect immediately, Veracyte said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.